[cube Pharmaceutical: application for Registration of Promevacaine Hydrochloride Eye Drops accepted] June 19, Cube Pharmaceutical announced that the company recently received a notice of acceptance of the application for drug registration of Promevacaine Hydrochloride eye drops (packed with low-density polyethylene single-dose eye drops) issued by the State Drug Administration. Promevacaine hydrochloride eye drops is mainly used for topical anesthesia in ophthalmology. It is a local anesthetic with rapid action and is suitable for ophthalmology.